The Journal of infection · 2010
Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Joung Mi Kyong, Kwon Ki Tae, Kang Cheol-In, Cheong Hae Suk, Rhee Ji-young, Jung Dong Sik, Chung Seung Min, Lee Jeong A, Moon Soo-youn, Ko Kwan Soo, Chung Doo Ryeon, Lee Nam Yong, Song Jae-Hoon, Peck Kyong Ran
Аннотация
OBJECTIVES: The purpose of this study was to evaluate the impact of inappropriate antimicrobial therapy on the outcome of patients with hospital-acquired pneumonia (HAP) caused by Acinetobacter baumannii.
METHODS: All cases of HAP caused by A. baumannii from January 2000 to March 2006 at the Samsung Medical Center (Seoul, Korea) were analyzed retrospectively.
RESULTS: A total of 116 patients with clinically significant Acinetobacter HAP were enrolled. Among the A. baumannii isolates, 60.3% showed multi-drug resistance (MDR), 16.4% were found to have imipenem resistance, and 15.5% had pan-drug resistance (PDR). The mean APACHE II score of the patients was 22.3 +/- 7.9. The overall in-hospital and pneumonia-related mortality rates were 47.4% and 37.9%, respectively. The univariate analysis showed that the factors associated with pneumonia-related mortality were: MDR, PDR, high APACHE II score, inappropriate empirical antimicrobial therapy, and inappropriate definitive antimicrobial treatment (All p < 0.05). Among these, a high APACHE II score and inappropriate definitive antimicrobial therapy were found to be independent factors associated with a high mortality, after adjustment for other variables.
CONCLUSIONS: The appropriate definitive antimicrobial therapy should be provided in patients with HAP caused by A. baumannii.
METHODS: All cases of HAP caused by A. baumannii from January 2000 to March 2006 at the Samsung Medical Center (Seoul, Korea) were analyzed retrospectively.
RESULTS: A total of 116 patients with clinically significant Acinetobacter HAP were enrolled. Among the A. baumannii isolates, 60.3% showed multi-drug resistance (MDR), 16.4% were found to have imipenem resistance, and 15.5% had pan-drug resistance (PDR). The mean APACHE II score of the patients was 22.3 +/- 7.9. The overall in-hospital and pneumonia-related mortality rates were 47.4% and 37.9%, respectively. The univariate analysis showed that the factors associated with pneumonia-related mortality were: MDR, PDR, high APACHE II score, inappropriate empirical antimicrobial therapy, and inappropriate definitive antimicrobial treatment (All p < 0.05). Among these, a high APACHE II score and inappropriate definitive antimicrobial therapy were found to be independent factors associated with a high mortality, after adjustment for other variables.
CONCLUSIONS: The appropriate definitive antimicrobial therapy should be provided in patients with HAP caused by A. baumannii.
Предметные рубрики MeSH
APACHEAcinetobacter InfectionsAcinetobacter baumanniiAdolescentAdultAgedAged, 80 and overAnalysis of VarianceAnti-Bacterial AgentsCross InfectionDrug Resistance, Multiple, BacterialFemaleHumansInappropriate PrescribingKaplan-Meier EstimateMaleMiddle AgedPneumonia, BacterialRetrospective StudiesRisk FactorsTreatment Outcome